The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 886 studies for Lymphoma, B-Cell across more than 10 countries. 286 are recruiting or about to start. 540 of them are mainly about Lymphoma, B-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 5 narrower conditions too, such as Lymphoma, Large B-Cell, Diffuse: 3,251 studies, 791 open.
ClinicalTrials.gov finds 4,727 studies for Lymphoma, B-Cell.How that becomes 885 here
This page counts the studies the registry files under Lymphoma, B-Cell, and those it files under no condition that list Lymphoma, B-Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
4,727Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−146List Lymphoma, B-Cell as a condition, but the registry did not file them under itMost often written as “DLBCL - Diffuse Large B Cell Lymphoma” (36), “Large B-cell Lymphoma” (14), and “Non-hodgkin Lymphoma,B Cell” (8). The registry filed them under other conditions only, most often Dendritic Cell Sarcoma, Interdigitating (43) and Recurrence (35).
−1,346Match it another way182 name it in the title, 19 in a keyword, and 1,145 by a synonym or other text the search reads.
885The count on this page105 of them list Lymphoma, B-Cell in their own words; the registry filed them under no condition.
Every program with a company-led study here in the last two years, whatever its size: 43 programs from 28 companies, 28 with this as their studies’ main aim; 6 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Beijing Biotech, AstraZeneca and Daiichi Sankyo here →
Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
+ Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone vs polatuzumab vedotinadded to Cyclophosphamideadded to Rituximab+4 more
The 5 in phase 3 with the nearest primary completion, of 43 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (5)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
31 Dec 2026 est.zamtocabtagene autoleucel· Miltenyi Biomedicine GmbH · Phase 2named, not the main aimstudied with Cyclophosphamidestudied with fludarabinestudied with bendamustineNCT04792489 DALY II USA/ MB-CART2019.1 for DLBCL — primary endpoint: Objective Response Rate · 315 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Lymphoma, B-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
111studies finish main data collection within a year6 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger. 37 (18%) take children under 18. 1 (<1%) are for women only and 0 (0%) for men only; 3 (1%) take healthy volunteers.
Across all 886 studies, recruiting or not: 30% stop at 75 or younger and 7% at 65; 15% take children; <1% are for women only and <1% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Lymphoma, B-Cell studies take
Of 207 phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 51 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
51 mo37–78 · 207 studies
47 mo37–81 · 90 studies
54 mo37–75 · 117 studies
Phase 1/2
71 mo55–96 · 94 studies
—
64 mo45–82 · 52 studies
Phase 2
53 mo34–73 · 120 studies
—
61 mo37–81 · 94 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.